Abstract: A pharmaceutical gel composition for intra-intestinal administration comprises (i) a dopamine replacement agent, (ii) a dopamine decarboxylase inhibitor (DDI), and (iii) a COMT inhibitor.

Abstract: The invention relates to a method of treating a dopamine related disorder in a subject, the method comprises the steps of administering therapy to a subject, the therapy comprising a plurality of doses of levodopa over a selected time period, in combination with a dopamine decarboxylase inhibitor (DDI) and a catechol-O-methyltransferase (COMT) inhibitor, wherein: (i) the dose of levodopa is lower; (ii) the dose of DDI is lower; (iii) the dosing of levodopa is less frequent; and/or (iv) the dosing of DDI is less frequent As compared with a reference regimen over the selected time period.

Abstract: A pharmaceutical gel composition for intra-intestinal administration comprises (i) a dopamine replacement agent, (ii) a dopamine decarboxylase inhibitor (DDI), and (iii) a COMT inhibitor.

Abstract: The invention relates to a method of treating a dopamine related disorder in a subject, the method comprises the steps of administering therapy to a subject, the therapy comprising a plurality of doses of levodopa over a selected time period, in combination with a dopamine decarboxylase inhibitor (DDI) and a catechol-O-methyltransferase (COMT) inhibitor, wherein: (i) the dose of levodopa is lower; (ii) the dose of DDI is lower; (iii) the dosing of levodopa is less frequent; and/or (iv) the dosing of DDI is less frequent As compared with a reference regimen over the selected time period.